Elia, S, Perrett, K, Newall, F. Providing opportunistic immunisations for at‐risk inpatients in a tertiary paediatric hospital.
Journal for Specialists in Pediatric Nursing
Littlejohn, E, Clothier, H, Perrett, K, Danchin, M. Surveillance of adverse events following the introduction of 13-valent pneumococcal conjugate vaccine in infants, and comparison with adverse events following 7-valent pneumococcal conjugate vaccine, in Victoria, Australia.
Human Vaccines & Immunotherapeutics
Perrett, KP, Nolan, TM, McVernon, J. A Licensed Combined Haemophilus influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine.
Infectious Diseases and Therapy
Nolan, T, O’Ryan, M, Santolaya, ME, De Looze, F, Marshall, H, Richmond, P, Henein, S, Rheault, P, Heaton, K, Perrett, K, et al. 152. Protective Antibody Levels 7.5 Years After Primary Vaccination in Adolescence With a Recombinant, 4-Component, Meningococcal Serogroup B Vaccine (4CMenB) and Response to a Booster Dose in Adolescents and Young Adults: Phase IIIb Clinical Findings.
Open Forum Infectious Diseases
Nolan, T, Santolaya, ME, de Looze, F, Marshall, H, Richmond, P, Henein, S, Rheault, P, Heaton, K, Perrett, KP, Garfield, H, et al. Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.